Cargando…
The ubiquitin ligase RNF2 stabilizes ERα and modulates breast cancer progression
Estrogen receptor α (ERα) is the most common clinical marker used for breast cancer prognosis and the classification of breast cancer subtypes. Clinically, patients with estrogen receptor-positive breast cancer can receive endocrine therapy. However, resistance to endocrine therapy has become an urg...
Autores principales: | Yuan, Lei, Li, Xin, Yang, Huijie, Li, Huixiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813066/ https://www.ncbi.nlm.nih.gov/pubmed/36271315 http://dx.doi.org/10.1007/s13577-022-00810-5 |
Ejemplares similares
-
The ubiquitin ligase RNF181 stabilizes ERα and modulates breast cancer progression
por: Zhu, Jian, et al.
Publicado: (2020) -
Atypical ubiquitin ligase RNF31: the nuclear factor modulator in breast cancer progression
por: Zhu, Jian, et al.
Publicado: (2016) -
Regulation of P53 signaling in breast cancer by the E3 ubiquitin ligase RNF187
por: Li, Xin, et al.
Publicado: (2022) -
The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor α and modulates estrogen-stimulated breast cancer cell proliferation
por: Zhu, J, et al.
Publicado: (2014) -
Regulation of Hippo signaling and triple negative breast cancer progression by an ubiquitin ligase RNF187
por: Wang, Zhonghao, et al.
Publicado: (2020)